Gilead Sciences Inc has made a dramatic entry to the field of regenerative medicine with an agreed bid for Kite Pharma Inc which has a portfolio of engineered cell therapies, the most advanced of which is under review in both the US and the EU. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
